PT3529234T - Compostos, processo para a obtenção dos compostos, composição farmacêutica, uso dos compostos e método para tratamento de distúrbios psiquiátricos e/ou distúrbios do sono - Google Patents
Compostos, processo para a obtenção dos compostos, composição farmacêutica, uso dos compostos e método para tratamento de distúrbios psiquiátricos e/ou distúrbios do sonoInfo
- Publication number
- PT3529234T PT3529234T PT178651550T PT17865155T PT3529234T PT 3529234 T PT3529234 T PT 3529234T PT 178651550 T PT178651550 T PT 178651550T PT 17865155 T PT17865155 T PT 17865155T PT 3529234 T PT3529234 T PT 3529234T
- Authority
- PT
- Portugal
- Prior art keywords
- compounds
- obtaining
- disorders
- pharmaceutical composition
- treating psychiatric
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 208000019116 sleep disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3529234T true PT3529234T (pt) | 2024-02-01 |
Family
ID=62023150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT178651550T PT3529234T (pt) | 2016-10-24 | 2017-10-23 | Compostos, processo para a obtenção dos compostos, composição farmacêutica, uso dos compostos e método para tratamento de distúrbios psiquiátricos e/ou distúrbios do sono |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10781182B2 (pt) |
| EP (2) | EP3529234B1 (pt) |
| JP (1) | JP7194683B2 (pt) |
| KR (1) | KR102594251B1 (pt) |
| CN (2) | CN115181108A (pt) |
| AR (1) | AR109467A1 (pt) |
| AU (1) | AU2017351756B2 (pt) |
| BR (2) | BR102016024814A2 (pt) |
| CA (1) | CA3042040A1 (pt) |
| CL (1) | CL2019001105A1 (pt) |
| CO (1) | CO2019004756A2 (pt) |
| DK (1) | DK3529234T3 (pt) |
| EC (1) | ECSP19032963A (pt) |
| ES (1) | ES2970546T3 (pt) |
| FI (1) | FI3529234T3 (pt) |
| MX (1) | MX2019004782A (pt) |
| PE (1) | PE20191046A1 (pt) |
| PT (1) | PT3529234T (pt) |
| SG (2) | SG11201903113TA (pt) |
| UY (1) | UY37334A (pt) |
| WO (1) | WO2018076090A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220255T1 (hr) | 2016-10-24 | 2022-04-29 | Astrazeneca Ab | Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izokinolina koji su korisni u liječenju raka |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
| FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| JP3559045B2 (ja) * | 1994-06-10 | 2004-08-25 | ナウチノ−イススレドバテルスキ インスティテュト ファルマコロギイ ロスシイスコイ アカデミイ メディツィンスキフ ナウク | 薬理学的活性を有する２−メルカプトベンズイミダゾール誘導体 |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
| US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| NZ335910A (en) | 1996-12-10 | 2000-11-24 | Bristol Myers Squibb Co | Benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane melatonergic agents useful in treating sleep disorders and circadian rhthym related disorders |
| US6214869B1 (en) | 1998-06-05 | 2001-04-10 | Bristol-Myers Squibb | Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| ATE257834T1 (de) | 1999-06-30 | 2004-01-15 | Bristol Myers Squibb Co | Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe |
| WO2003062224A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| US20070191447A1 (en) | 2004-02-23 | 2007-08-16 | Toru Kodo | Novel heterocyclic compound |
| ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
| US20090298811A1 (en) * | 2006-09-12 | 2009-12-03 | Pfizer Inc | Benzimidazolone derivatives |
| EP2088861A4 (en) * | 2006-10-25 | 2010-07-07 | Takeda Pharmaceutical | BENZIMIDAZOLE COMPOUNDS |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001037334A patent/UY37334A/es unknown
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es unknown
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active IP Right Grant
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 CA CA3042040A patent/CA3042040A1/en active Pending
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 BR BR112019008197A patent/BR112019008197A2/pt active Search and Examination
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 MX MX2019004782A patent/MX2019004782A/es unknown
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
- 2017-10-23 EP EP20185268.8A patent/EP3741760A1/en active Pending
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en active Application Filing
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| HRP20210518T1 (hr) | Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava | |
| IL266596A (en) | Causes, uses and methods of treating synovialitis | |
| IL269599A (en) | 11, 13- modified schistosoxins for pain treatment | |
| EP3149205A4 (en) | Method for diagnostics, treatment and prevention of parkinson's disease | |
| PL3142785T3 (pl) | Sposób wytwarzania alkenoli i ich zastosowanie do wytwarzania 1,3- butadienu | |
| IL266047A (en) | Methods and preparations for the treatment of Fabry disease | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| HK1251168A1 (zh) | 用於治療和/或預防腫瘤的沙粒病毒和產生具有(改善的)腫瘤消退特性的沙粒病毒的方法 | |
| SG10202009001TA (en) | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | |
| EP3606598A4 (en) | METHOD OF NEURAL INTERVENTION FOR TREATMENT OF AFFECTIVE NEUROPSYCHIATRIC DISORDERS | |
| EP3677265A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF SLEEP DISORDERS | |
| PT3458467T (pt) | Processo para a epoxidação 6,7-alfa de esteroide-4,6-dienos | |
| IL259674B (en) | Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases | |
| SI3452465T1 (sl) | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni | |
| PL3247651T3 (pl) | Pojemnik ze środkiem do traktowania oraz sposób jego wytwarzania | |
| EP3423063A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SEARCH OR SUBSTANCE ABUSE MISTAKES | |
| PL3374074T3 (pl) | Urządzenie i sposób wytwarzania formaldehydu | |
| HUE049463T2 (hu) | Eljárás kavicsok kezelésére | |
| EP3501494A4 (en) | ANTI-WRINKLE COSMETIC COMPOSITION, USE OF THIS COMPOSITION AND ANTI-WRINKLE TREATMENT METHOD | |
| EP3251699A4 (en) | Composition and method for treatment of neuropsychiatric disorders | |
| HK1255631A1 (zh) | 用於預防和治療睡眠障礙的藥物組合物 | |
| ZA201906542B (en) | Process for the treatment of wastewater |